When did Ionis Pharmaceuticals report Q4 2024 earnings?

Ionis Pharmaceuticals (IONS) reported Q4 2024 earnings on February 19, 2025 before market open.

What were Ionis Pharmaceuticals's Q4 2024 revenue and EPS?

Ionis Pharmaceuticals reported revenue of $226.6M and diluted EPS of $-0.66 for Q4 2024.

Did Ionis Pharmaceuticals beat estimates in Q4 2024?

Revenue beat the consensus estimate of $131.1M by $95.4M. EPS beat the consensus estimate of $-1.09 by $0.43.

Where can I find Ionis Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000874015-25-000089) directly on SEC EDGAR. The filing index links above go to sec.gov.

Ionis Pharmaceuticals IONS Q4 2024 Annual earnings

Reported February 19, 2025 · Before market open

Revenue$226.6MBeat by $95.4M Diluted EPS-$0.66Beat by $0.43

Revenue estimate$131.1M

EPS estimate-$1.09

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$190.4M

EPS estimate-$0.92

Financials

Q4 2024

Income statement

See full

Revenue$226.6M-30.2%

Gross profit$222.7M-30.7%

Operating income-$110.8M-1,710%

Net income-$104.3M-1,027%

EPS (diluted)-$0.66-1,000%

Balance sheet

See full

Cash & equivalents$242.1M-39.4%

Total debt$223.0M-16.0%

Total equity$588.4M+52.2%

Total assets$3.0B+0.5%

Cash flow

See full

Operating cash flow-$116.1M-51.1%

CapEx$25.5M—

Free cash flow-$141.6M-71.0%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$5.52B-24.2%

Enterprise value$5.5B-23.1%

P/S7.8×-1.4×

Profitability

See full

Gross margin98.4%-0.4pp

Operating margin-67.4%+67.4pp

Net margin-64.4%+40.2pp

FCF margin-77.5%+44.0pp

Returns & leverage

See full

Return on equity-93.1%+26.2pp

Debt / equity0.4×-0.3×

Current ratio8.5×+2.6×

Segments

By product

See full

Research And Development Revenue$140.9M-42.7%

Collaborative Agreement Revenue$96.9M—

Commercial$85.7M—

Spinraza Royalties$63.7M+2.9%

Wainua Joint Development Revenue$44.0M—

By segment

See full

Ionis Operations$226.6M+15.1%

Versus estimates

Revenue

Q1 2026$246.0MBeat by $50.4M Q4 2025$203.0MBeat by $46.9M Q4 2025$156.7MBeat by $3.1M Q2 2025$452.0MBeat by $320.3M Q1 2025$131.6MMiss by $19.0M

Q4 2024$226.6MBeat by $95.4M

Diluted EPS

Q1 2026-$0.56Beat by $0.29 Q4 2025-$1.41Miss by $0.17 Q4 2025-$0.61Beat by $0.54 Q2 2025$0.86Beat by $0.59 Q1 2025-$0.75Beat by $0.36

Q4 2024-$0.66Beat by $0.43

Ask the moment Ionis Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Ionis Pharmaceuticals report Q4 2024 earnings?: Ionis Pharmaceuticals (IONS) reported Q4 2024 earnings on February 19, 2025 before market open.
What were Ionis Pharmaceuticals's Q4 2024 revenue and EPS?: Ionis Pharmaceuticals reported revenue of $226.6M and diluted EPS of $-0.66 for Q4 2024.
Did Ionis Pharmaceuticals beat estimates in Q4 2024?: Revenue beat the consensus estimate of $131.1M by $95.4M. EPS beat the consensus estimate of $-1.09 by $0.43.
Where can I find Ionis Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000874015-25-000089) directly on SEC EDGAR. The filing index links above go to sec.gov.